4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes – P&T Community

Related Articles:

• 4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes - Yahoo Finance September 23, 2019 4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes  Yahoo Finance4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029. LEEDS, England, Sept. 23, 2019 ...
• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society September 25, 2019 JERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday...
• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society - Yahoo Finance September 25, 2019 Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society  Yahoo FinanceJERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the ...
• Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome - GlobeNewswire November 6, 2019 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome  GlobeNewswire
• Herantis Pharma Plc: Update on contemplated directed share issue - GlobeNewswire March 12, 2019 Herantis Pharma Plc: Update on contemplated directed share issue  GlobeNewswireHerantis Pharma Plc: Update on contemplated directed share issue. Herantis Pharma Plc Company release 12 March 2019 at 12:30 pm. Not for publication or ...
• Acadia Pharma Jumps on Positive Data From Depression Treatment Candidate - TheStreet.com September 23, 2019 Acadia Pharma Jumps on Positive Data From Depression Treatment Candidate  TheStreet.comAcadia announces positive results from an eight-week, open label, phase 2 study for a treatment candidate for Parkinson's patients with depressive symptoms.
• Adamas Pharma (ADMS) Announces New Safety and Efficacy Data for GOCOVRI in Parkinson's Disease Patients with Dyskinesia at MDS - StreetInsider.com September 20, 2019 Adamas Pharma (ADMS) Announces New Safety and Efficacy Data for GOCOVRI in Parkinson's Disease Patients with Dyskinesia at MDS  StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), ...
• Intec Pharma Granted European Patent - P&T Community May 20, 2019 Intec Pharma Granted European Patent  P&T CommunityJERUSALEM, May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the European Patent Office ...
• Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society - P&T Community September 16, 2019 Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society  P&T CommunityJERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the ...
• Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson's Disease - Nasdaq June 18, 2019 Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson's Disease  NasdaqNovel retrospective analysis of GOCOVRI® pooled Phase 3 Parkinson's disease diary data, presented at the International Association of Parkinsonism and ...
• Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference - P&T Community March 13, 2019 Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference  P&T CommunityJERUSALEM, March 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company's ...
• Intec Pharma to Participate at June Investment Conferences - P&T Community May 28, 2019 Intec Pharma to Participate at June Investment Conferences  P&T CommunityJERUSALEM, May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will ...
• Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson's Disease - GlobeNewswire June 18, 2019 Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson's Disease  GlobeNewswireNovel retrospective analysis of GOCOVRI® pooled Phase 3 Parkinson's disease diary data, presented at the International Association of Parkinsonism and ...
• Shimmer and ClearSky team up to improve wearable data analysis - OutSourcing-Pharma.com July 1, 2019 Shimmer and ClearSky team up to improve wearable data analysis  OutSourcing-Pharma.comSponsors to benefit from more accurate, shorter, and less costly trials through Shimmer Research and ClearSky Medical Diagnostics partnerships, says ...
• 4D Announces Participation in Neuro4D Conference, Frankfurt, Germany - P&T Community May 13, 2019 4D Announces Participation in Neuro4D Conference, Frankfurt, Germany  P&T CommunityLEEDS, England, May 13, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, ...
• BRIEF—Positive data for Parkinson's candidate - The Pharma Letter May 7, 2019 BRIEF—Positive data for Parkinson's candidate  The Pharma LetterNeurocrine Biosciences has been buoyed by positive data from two Phase III studies of its Parkinson's disease candidate opicapone, presented at the annual ...
• Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders - P&T Community September 23, 2019 Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders  P&T CommunityJERSEY CITY, N.J., Sept. 23, 2019 /PRNewswire/ -- Mitsubishi Tanabe Pharma Corporation Group announced today the presentation of an analysis of ...
• Intec Pharma Announces Research Collaboration Agreement With Merck - Yahoo Finance May 16, 2019 Intec Pharma Announces Research Collaboration Agreement With Merck  Yahoo Finance"We are very excited to collaborate with Merck," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "We believe this program, ...
• Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders - Yahoo Finance May 2, 2019 Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders  Yahoo FinanceJERUSALEM , May 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a ...
• Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society - Yahoo Finance September 16, 2019 Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society  Yahoo FinanceJERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that two posters in support of the ...